CYTOKINETICS INC 8-K

What Happened CYTOKINETICS, Inc. (CYTK) filed an 8‑K on May 27, 2026 reporting results from its Annual Meeting of Stockholders held that day. A quorum was present (116,125,730 of 124,237,822 shares, or 93.47%). Stockholders elected three Class I directors—Edward M. Kaye, M.D.; Wendell Wierenga, Ph.D.; and Nancy J. Wysenski—and voted on corporate governance and compensation matters.

Key Details

• Board elections: Edward M. Kaye — For 104,633,356; Withheld 3,234,862; Broker non‑vote 8,257,512. Wendell Wierenga — For 85,427,010; Withheld 22,441,208; Broker non‑vote 8,257,512. Nancy J. Wysenski — For 104,820,911; Withheld 3,047,307; Broker non‑vote 8,257,512.
• Employee Stock Purchase Plan (ESPP): Shareholders approved amending the 2015 ESPP to add 1,000,000 authorized shares (For 107,254,415; Against 261,354; Abstain 352,449; Broker non‑vote 8,257,512).
• Auditor ratification: Ernst & Young LLP was ratified as independent registered public accounting firm for FY2026 (For 115,468,025; Against 269,258; Abstain 388,447; no broker non‑votes).
• Advisory vote on executive compensation: Approved on an advisory basis (For 104,005,531; Against 3,018,095; Abstain 844,592; Broker non‑vote 8,257,512).

Why It Matters These results confirm the company’s board composition and governance direction, show shareholder support for the ESPP share increase (which may modestly increase share reserve/dilution over time), and maintain continuity with Ernst & Young as auditor. For investors, the votes indicate general shareholder endorsement of management and compensation policies and preserve the company’s ability to issue additional shares under the ESPP.